Alessandro Leal

Dr. Alessandro Leal

orcid

Research Focus & Metrics

Representative Publications

View All Publications
29 May 2019 in Nature
Verified
Journal Article
Closed access
PDF file
SCStephen Cristiano
Stephen Cristiano
ALAlessandro Leal
Alessandro Leal
JPJillian Phallen
Jillian Phallen
JFJacob Fiksel
Jacob Fiksel
VAVilmos Adleff
Vilmos Adleff
VVVictor E. Velculescu
Victor E. Velculescu

16 August 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JPJillian Phallen
Jillian Phallen
MSMark Sausen
Mark Sausen
VAVilmos Adleff
Vilmos Adleff
ALAlessandro Leal
Alessandro Leal
CHCarolyn Hruban
Carolyn Hruban
VVVictor E. Velculescu
Victor E. Velculescu
Noninvasive liquid biopsy analysis of circulating tumor DNA permits direct detection of early-stage cancers.

20 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDimitrios Mathios
Dimitrios Mathios
JJJakob Sidenius Johansen
Jakob Sidenius Johansen
SCStephen Cristiano
Stephen Cristiano
JMJamie E. Medina
Jamie E. Medina
JPJillian Phallen
Jillian Phallen
VVVictor E. Velculescu
Victor E. Velculescu
Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of cfDNA fragmentation in a prospective study of 365 individuals at risk for lung cancer. We validate the cancer detection model using an independent cohort of 385 non-cancer individuals and 46 lung cancer patients. Combining fragmentation features, clinical risk factors, and CEA levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stage III/IV, at 80% specificity. Genome-wide fragmentation profiles across ~13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy (AUC = 0.98). A higher fragmentation score represented an independent prognostic indicator of survival. This approach provides a facile avenue for non-invasive detection of lung cancer.

15 March 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
VAValsamo Anagnostou
Valsamo Anagnostou
PFPatrick M. Forde
Patrick M. Forde
JWJames R. White
James R. White
NNNoushin Niknafs
Noushin Niknafs
CHCarolyn Hruban
Carolyn Hruban
VVVictor E. Velculescu
Victor E. Velculescu
Despite the initial successes of immunotherapy, there is an urgent clinical need for molecular assays that identify patients more likely to respond. Here, we report that ultrasensitive measures of circulating tumor DNA (ctDNA) and T-cell expansion can be used to assess responses to immune checkpoint blockade in metastatic lung cancer patients (N = 24). Patients with clinical response to therapy had a complete reduction in ctDNA levels after initiation of therapy, whereas nonresponders had no significant changes or an increase in ctDNA levels. Patients with initial response followed by acquired resistance to therapy had an initial drop followed by recrudescence in ctDNA levels. Patients without a molecular response had shorter progression-free and overall survival compared with molecular responders [5.2 vs. 14.5 and 8.4 vs. 18.7 months; HR 5.36; 95% confidence interval (CI), 1.57–18.35; P = 0.007 and HR 6.91; 95% CI, 1.37–34.97; P = 0.02, respectively], which was detected on average 8.7 weeks earlier and was more predictive of clinical benefit than CT imaging. Expansion of T cells, measured through increases of T-cell receptor productive frequencies, mirrored ctDNA reduction in response to therapy. We validated this approach in an independent cohort of patients with early-stage non–small cell lung cancer (N = 14), where the therapeutic effect was measured by pathologic assessment of residual tumor after anti-PD1 therapy. Consistent with our initial findings, early ctDNA dynamics predicted pathologic response to immune checkpoint blockade. These analyses provide an approach for rapid determination of therapeutic outcomes for patients treated with immune checkpoint inhibitors and have important implications for the development of personalized immune targeted strategies. Significance: Rapid and sensitive detection of circulating tumor DNA dynamic changes and T-cell expansion can be used to guide immune targeted therapy for patients with lung cancer. See related commentary by Zou and Meyerson, p. 1038

27 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ALAlessandro Leal
Alessandro Leal
Nicole van GriekenNicole van Grieken
Nicole van Grieken
DPDoreen N. Palsgrove
Doreen N. Palsgrove
JPJillian Phallen
Jillian Phallen
JMJamie E. Medina
Jamie E. Medina
VVVictor E. Velculescu
Victor E. Velculescu
Liquid biopsies are providing new opportunities for detection of residual disease in cell-free DNA (cfDNA) after surgery but may be confounded through identification of alterations arising from clonal hematopoiesis. Here, we identify circulating tumor-derived DNA (ctDNA) alterations through ultrasensitive targeted sequencing analyses of matched cfDNA and white blood cells from the same patient. We apply this approach to analyze samples from patients in the CRITICS trial, a phase III randomized controlled study of perioperative treatment in patients with operable gastric cancer. After filtering alterations from matched white blood cells, the presence of ctDNA predicts recurrence when analyzed within nine weeks after preoperative treatment and after surgery in patients eligible for multimodal treatment. These analyses provide a facile method for distinguishing ctDNA from other cfDNA alterations and highlight the utility of ctDNA as a predictive biomarker of patient outcome to perioperative cancer therapy and surgical resection in patients with gastric cancer.

15 March 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JPJillian Phallen
Jillian Phallen
ALAlessandro Leal
Alessandro Leal
BWBrian D. Woodward
Brian D. Woodward
PFPatrick M. Forde
Patrick M. Forde
JNJarushka Naidoo
Jarushka Naidoo
HHHatim Husain
Hatim Husain
With the advent of precision oncology, there is an urgent need to develop improved methods for rapidly detecting responses to targeted therapies. Here, we have developed an ultrasensitive measure of cell-free tumor load using targeted and whole-genome sequencing approaches to assess responses to tyrosine kinase inhibitors in patients with advanced lung cancer. Analyses of 28 patients treated with anti-EGFR or HER2 therapies revealed a bimodal distribution of cell-free circulating tumor DNA (ctDNA) after therapy initiation, with molecular responders having nearly complete elimination of ctDNA (>98%). Molecular nonresponders displayed limited changes in ctDNA levels posttreatment and experienced significantly shorter progression-free survival (median 1.6 vs. 13.7 months, P < 0.0001; HR = 66.6; 95% confidence interval, 13.0–341.7), which was detected on average 4 weeks earlier than CT imaging. ctDNA analyses of patients with radiographic stable or nonmeasurable disease improved prediction of clinical outcome compared with CT imaging. These analyses provide a rapid approach for evaluating therapeutic response to targeted therapies and have important implications for the management of patients with cancer and the development of new therapeutics. Significance: Cell-free tumor load provides a novel approach for evaluating longitudinal changes in ctDNA during systemic treatment with tyrosine kinase inhibitors and serves an unmet clinical need for real-time, noninvasive detection of tumor response to targeted therapies before radiographic assessment. See related commentary by Zou and Meyerson, p. 1038